Lilly announced results from its Phase 3 TRIUMPH-4 trial of retatrutide, a first-in-class GIP, GLP-1 and glucagon triple hormone receptor agonist, on Thursday. In the efficacy-estimand analysis, participants taking the highest dose (12 mg) lost an average of 28.7% of their body weight at 68 weeks, about 71.2 pounds from a baseline of 248.5 pounds.…